<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27788239</article-id><article-id pub-id-type="pmc">5082792</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0165631</article-id><article-id pub-id-type="publisher-id">PONE-D-16-31430</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pharmacology</subject><subj-group><subject>Drug Interactions</subject><subj-group><subject>Drug-Drug Interactions</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>People and Places</subject><subj-group><subject>Population Groupings</subject><subj-group><subject>Ethnicities</subject><subj-group><subject>Africans</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Medical Microbiology</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Immunodeficiency Viruses</subject><subj-group><subject>HIV</subject><subj-group><subject>HIV-1</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pathology and Laboratory Medicine</subject><subj-group><subject>Pathogens</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Immunodeficiency Viruses</subject><subj-group><subject>HIV</subject><subj-group><subject>HIV-1</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Immunodeficiency Viruses</subject><subj-group><subject>HIV</subject><subj-group><subject>HIV-1</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>Immunodeficiency Viruses</subject><subj-group><subject>HIV</subject><subj-group><subject>HIV-1</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>RNA viruses</subject><subj-group><subject>Retroviruses</subject><subj-group><subject>Lentivirus</subject><subj-group><subject>HIV</subject><subj-group><subject>HIV-1</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Medical Microbiology</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Retroviruses</subject><subj-group><subject>Lentivirus</subject><subj-group><subject>HIV</subject><subj-group><subject>HIV-1</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pathology and Laboratory Medicine</subject><subj-group><subject>Pathogens</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Retroviruses</subject><subj-group><subject>Lentivirus</subject><subj-group><subject>HIV</subject><subj-group><subject>HIV-1</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Retroviruses</subject><subj-group><subject>Lentivirus</subject><subj-group><subject>HIV</subject><subj-group><subject>HIV-1</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pharmacology</subject><subj-group><subject>Drug Interactions</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>Genetic Loci</subject><subj-group><subject>Alleles</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pharmaceutics</subject><subj-group><subject>Drug Therapy</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Molecular Biology</subject><subj-group><subject>Molecular Biology Techniques</subject><subj-group><subject>Genotyping</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Molecular Biology Techniques</subject><subj-group><subject>Genotyping</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pharmacology</subject><subj-group><subject>Pharmacokinetics</subject><subj-group><subject>Drug Metabolism</subject></subj-group></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Interaction between Darunavir and Etravirine Is Partly Mediated by <italic>CYP3A5</italic> Polymorphism</article-title><alt-title alt-title-type="running-head">Interaction Darunavir-Etravirine and <italic>CYP3A5</italic> Polymorphism</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Belkhir</surname><given-names>Le&#x000ef;la</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref><xref ref-type="corresp" rid="cor001">*</xref></contrib><contrib contrib-type="author"><name><surname>Elens</surname><given-names>Laure</given-names></name><xref ref-type="aff" rid="aff002"><sup>2</sup></xref><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Zech</surname><given-names>Francis</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Panin</surname><given-names>Nadtha</given-names></name><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Vincent</surname><given-names>Anne</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Yombi</surname><given-names>Jean Cyr</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Vandercam</surname><given-names>Bernard</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Haufroid</surname><given-names>Vincent</given-names></name><xref ref-type="aff" rid="aff002"><sup>2</sup></xref><xref ref-type="aff" rid="aff004"><sup>4</sup></xref></contrib></contrib-group><aff id="aff001"><label>1</label>
<addr-line>AIDS Reference Center, Department of Internal Medicine, Cliniques universitaires Saint-Luc, Universit&#x000e9; catholique de Louvain, Brussels, Belgium</addr-line></aff><aff id="aff002"><label>2</label>
<addr-line>Louvain centre for Toxicology and Applied Pharmacology, Institut de recherche exp&#x000e9;rimentale et clinique, Universit&#x000e9; catholique de Louvain, Brussels, Belgium</addr-line></aff><aff id="aff003"><label>3</label>
<addr-line>Integrated PharmacoMetrics, PharmacoGenomics and PharmacoKinetics, Louvain Drug Research Institute, Universit&#x000e9; catholique de Louvain, Brussels, Belgium</addr-line></aff><aff id="aff004"><label>4</label>
<addr-line>Department of Clinical Chemistry, Cliniques universitaires Saint-Luc, Universit&#x000e9; catholique de Louvain, Brussels, Belgium</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>De Socio</surname><given-names>Giuseppe Vittorio</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1"><addr-line>Azienda Ospedaliera Universitaria di Perugia, ITALY</addr-line></aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="con"><p><list list-type="simple"><list-item><p><bold>Conceptualization:</bold> LB LE BV VH.</p></list-item><list-item><p><bold>Data curation:</bold> LB AV.</p></list-item><list-item><p><bold>Formal analysis:</bold> LB LE FZ.</p></list-item><list-item><p><bold>Funding acquisition:</bold> LB VH.</p></list-item><list-item><p><bold>Investigation:</bold> LB NP.</p></list-item><list-item><p><bold>Methodology:</bold> LB LE VH.</p></list-item><list-item><p><bold>Project administration:</bold> LB.</p></list-item><list-item><p><bold>Resources:</bold> NP.</p></list-item><list-item><p><bold>Supervision:</bold> VH BV.</p></list-item><list-item><p><bold>Visualization:</bold> LB LE VH.</p></list-item><list-item><p><bold>Writing &#x02013; original draft:</bold> LB.</p></list-item><list-item><p><bold>Writing &#x02013; review &#x00026; editing:</bold> LB LE AV JCY BV VH.</p></list-item></list></p></fn><corresp id="cor001">* E-mail: <email>leila.belkhir@uclouvain.be</email></corresp></author-notes><pub-date pub-type="epub"><day>27</day><month>10</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>11</volume><issue>10</issue><elocation-id>e0165631</elocation-id><history><date date-type="received"><day>5</day><month>8</month><year>2016</year></date><date date-type="accepted"><day>15</day><month>10</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9; 2016 Belkhir et al</copyright-statement><copyright-year>2016</copyright-year><copyright-holder>Belkhir et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pone.0165631.pdf"/><abstract><sec id="sec001"><title>Objectives</title><p>To assess the impact of the loss-of-function <italic>CYP3A5*3</italic> allele (rs776746, 6986A&#x0003e;G SNP) on darunavir (DRV) plasma concentrations.</p></sec><sec id="sec002"><title>Methods</title><p>135 HIV-1 infected patients treated with DRV-based therapy were included in the study and plasma samples were obtained immediately before drug intake in order to determine DRV trough concentrations using an ultra performance liquid chromatography method (UPLC) with diode-array detection (DAD). Noteworthy is the fact that in 16 (11.9%) patients, etravirine (ETR) was combined with DRV. <italic>CYP3A5</italic> genotypes were determined using real time PCR method (TaqMan&#x000ae; genotyping assay). The patients were then classified into CYP3A5 expressors (<italic>CYP3A5*1</italic> allele carriers) and non-expressors (<italic>CYP3A5*3</italic> homozygous). Subsequently, the association between DRV plasma trough concentration ([DRV]<sub>plasma</sub>) and CYP3A5 genotype-based expression status was analyzed.</p></sec><sec id="sec003"><title>Results</title><p>45% of the patients were classified as CYP3A5 expressors. In the whole cohort, mean [DRV]<sub>plasma</sub> was not different between CYP3A5 expressors and non-expressors (1894ng/ml [CI95%: 1566&#x02013;2290] versus 1737ng/ml [CI95%: 1468&#x02013;2057], p = 0.43). However, in the subgroup of the 16 patients receiving DRV combined with ETR, a significantly lower [DRV]<sub>plasma</sub> was observed for CYP3A5 expressors when compared to non-expressors (1385ng/ml [CI95%:886.3&#x02013;2165] versus 3141ng/ml [CI95%:2042&#x02013;4831], p = 0.007).</p></sec><sec id="sec004"><title>Conclusions</title><p>Interaction between DRV and ETR is partly mediated by <italic>CYP3A5</italic> polymorphism with lower DRV plasma trough concentrations in CYP3A5 expressors suggesting a specific ETR-driven CYP3A5 activation only in CYP3A5 expressors. Consequently, these patients might be more at risk of infra-therapeutic [DRV]<sub>plasma</sub>. This potentially important observation is a good illustration of a genotype-based drug interaction, which could also have considerable consequences if translated to other CYP3A5-metabolized drugs. Further investigations are thus needed to confirm this association and to explore its clinical impact, mainly in the African population among whom CYP3A5 expressors are more frequent, before recommending systematic CYP3A5 pre-emptive genotyping for DRV-ETR co-administration.</p></sec></abstract><funding-group><award-group id="award001"><funding-source><institution>Fondation Saint-Luc</institution></funding-source><principal-award-recipient><name><surname>Belkhir</surname><given-names>Leila</given-names></name></principal-award-recipient></award-group><award-group id="award002"><funding-source><institution>Fonds Pierre et Colette Bauchau</institution></funding-source><principal-award-recipient><name><surname>Belkhir</surname><given-names>Leila</given-names></name></principal-award-recipient></award-group><funding-statement>Le&#x000ef;la Belkhir is a doctoral researcher with the Fondation Saint-Luc (Cliniques universitaires Saint-Luc, Belgium) and with the Fonds Pierre et Colette Bauchau (UCL, Belgium). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><fig-count count="1"/><table-count count="3"/><page-count count="13"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>All relevant data are within the paper.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>All relevant data are within the paper.</p></notes></front><body><sec sec-type="intro" id="sec005"><title>Introduction</title><p>Darunavir (Prezista&#x000ae; DRV) is the most recent potent protease inhibitor (PI) used as a component of highly active antiretroviral therapy (HAART) in combination with the pharmacokinetic (PK) booster ritonavir (association hereafter defined as DRV/r) for the treatment of Human Immunodeficiency Virus-1 (HIV-1) infected patients [<xref rid="pone.0165631.ref001" ref-type="bibr">1</xref>, <xref rid="pone.0165631.ref002" ref-type="bibr">2</xref>]. DRV has demonstrated potent <italic>in vitro</italic> and <italic>in vivo</italic> activity against both wild-type (WT) and PI-resistant HIV [<xref rid="pone.0165631.ref003" ref-type="bibr">3</xref>&#x02013;<xref rid="pone.0165631.ref005" ref-type="bibr">5</xref>].</p><p>Initially, DRV/r regimen was approved at a dose of 600mg/100mg twice daily for treatment-experienced HIV-infected patients on the basis of clinical efficacy and safety data collected in the POWER 1 and 2 trials [<xref rid="pone.0165631.ref003" ref-type="bibr">3</xref>, <xref rid="pone.0165631.ref006" ref-type="bibr">6</xref>, <xref rid="pone.0165631.ref007" ref-type="bibr">7</xref>].</p><p>Later, in the ARTEMIS trial, the efficacy of a DRV/r once daily regimen (800/100 mg) was demonstrated in treatment-na&#x000ef;ve patients. The study revealed that DRV/r QD was not only non-inferior but also, significantly superior in terms of virologic response when compared to lopinavir/ritonavir after 96 weeks in antiretroviral-naive patients [<xref rid="pone.0165631.ref008" ref-type="bibr">8</xref>]. Consequently, DRV was approved at two different daily dosages depending on the clinical setting and the genotypic testing of the virus.</p><p>As many other PI, DRV is a substrate and inhibitor of CYP3A enzymes and is almost exclusively metabolized by these CYP3A isoforms [<xref rid="pone.0165631.ref004" ref-type="bibr">4</xref>, <xref rid="pone.0165631.ref006" ref-type="bibr">6</xref>, <xref rid="pone.0165631.ref009" ref-type="bibr">9</xref>]. DRV is also a substrate of the efflux transporter P-glycoprotein (P-gp) [<xref rid="pone.0165631.ref006" ref-type="bibr">6</xref>]. Ritonavir (RTV) is a potent inhibitor of CYP3A that reduces DRV clearance, resulting in a 14-fold increase of DRV exposure and extends DRV half-life up to 15 hours [<xref rid="pone.0165631.ref010" ref-type="bibr">10</xref>].</p><p>Etravirine (Intelence&#x000ae; ETR) is a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) that possesses an activity against both WT and NNRTI-resistant HIV [<xref rid="pone.0165631.ref011" ref-type="bibr">11</xref>, <xref rid="pone.0165631.ref012" ref-type="bibr">12</xref>] and a high genetic barrier against the development of drug resistance. Two studies (DUET-1 and DUET-2) [<xref rid="pone.0165631.ref013" ref-type="bibr">13</xref>, <xref rid="pone.0165631.ref014" ref-type="bibr">14</xref>] conducted in clinically advanced, treatment-experienced patients with viral strains harboring NNRTI and PI resistances have shown superiority of ETR to the placebo in terms of virological efficacy, immunological recovery and clinical progression. Noteworthy in this difficult-to-treat population, ETR was associated with an optimized background regimen (OBR) that included DRV/r 600/100 mg BID.</p><p>ETR is primarily metabolized in the liver via CYP2C19, CYP2C9, and CYP3A [<xref rid="pone.0165631.ref015" ref-type="bibr">15</xref>]. ETR is also a weak inducer of CYP3A4 [<xref rid="pone.0165631.ref016" ref-type="bibr">16</xref>] (by increasing the abundance of CYP3A4 mRNA in a pregnane X receptor (PXR) dependent manner) [<xref rid="pone.0165631.ref017" ref-type="bibr">17</xref>] and an inhibitor of CYP2C9, CYP2C19 and P-gp [<xref rid="pone.0165631.ref015" ref-type="bibr">15</xref>, <xref rid="pone.0165631.ref016" ref-type="bibr">16</xref>, <xref rid="pone.0165631.ref018" ref-type="bibr">18</xref>]. It has been previously demonstrated that the <italic>CYP3A5</italic> gene is inducible by mechanisms similar to those involved in <italic>CYP3A4</italic> induction, involving constitutively activated receptor (CAR) and PXR [<xref rid="pone.0165631.ref019" ref-type="bibr">19</xref>]. Therefore, as an established CYP3A4 inducer [<xref rid="pone.0165631.ref016" ref-type="bibr">16</xref>], ETR could also be considered as a potential CYP3A5 inducer but only in individuals expressing this isoform (see below). The CYP3A induction and P-gp inhibition driven by ETR has the potential to alter DRV disposition and therefore, theoretically, there exists a potential hazard of drug-drug interactions between these agents.</p><p>The CYP3A proteins (mainly CYP3A4 followed by CYP3A5) are the most abundant cytochrome P450 (CYP) proteins in human liver and small intestine and they metabolize around 50% of drugs currently in use [<xref rid="pone.0165631.ref020" ref-type="bibr">20</xref>]. While functional genetic polymorphisms for <italic>CYP3A4</italic> genes are rare [<xref rid="pone.0165631.ref021" ref-type="bibr">21</xref>], CYP3A5 activity highly depends on genetic status of the patient [<xref rid="pone.0165631.ref022" ref-type="bibr">22</xref>].</p><p>The most common loss-of-function variant of <italic>CYP3A5</italic> is designated as <italic>CYP3A5*3</italic> (rs776746, 6986A &#x0003e; G) [<xref rid="pone.0165631.ref022" ref-type="bibr">22</xref>, <xref rid="pone.0165631.ref023" ref-type="bibr">23</xref>]. This single nucleotide polymorphism (SNP) consisting of a substitution within intron 3 creates a cryptic splice site, affecting mRNA splicing and resulting in a premature stop codon that finally gives rise to the translation of a truncated nonfunctional protein [<xref rid="pone.0165631.ref022" ref-type="bibr">22</xref>, <xref rid="pone.0165631.ref023" ref-type="bibr">23</xref>]. Consequently, only carriers of at least one <italic>CYP3A5*1</italic> (wild-type) allele are expressing a functional CYP3A5 enzyme whereas individuals homozygous for the loss-of-function allele (<italic>CYP3A5*3/*3)</italic> are considered to be CYP3A5 non-expressors.</p><p>Furthermore, distribution of <italic>CYP3A5</italic> polymorphisms varies greatly across the globe with the <italic>CYP3A5*3</italic> allele occurring with different frequencies among ethnic populations. The CYP3A5*3 allele is abundantly present in Caucasian population but rare in African population (allelic frequency of 91&#x02013;95% [<xref rid="pone.0165631.ref023" ref-type="bibr">23</xref>, <xref rid="pone.0165631.ref024" ref-type="bibr">24</xref>] and 27% [<xref rid="pone.0165631.ref023" ref-type="bibr">23</xref>], respectively). Therefore, CYP3A5 expressors are mainly encountered in the population of African origin.</p><p>In Western and Central Europe, in 2014, 37% of all new HIV infections occurred among migrants from outside of this region[<xref rid="pone.0165631.ref025" ref-type="bibr">25</xref>]. For example, in the UK in 2014, 55% of men and 62% of women living with HIV were from sub-Saharan Africa; in Belgium, when the data was available, almost 30% of the newly infected HIV people were of African origin [<xref rid="pone.0165631.ref026" ref-type="bibr">26</xref>]. In the USA in 2013, 46% (506000) of people living with HIV were African Americans, representing on the whole, 12% of the US population [<xref rid="pone.0165631.ref027" ref-type="bibr">27</xref>].</p><p>Considering that CYP3A5 may represent up to 50% of the total hepatic CYP3A content in <italic>CYP3A5*1</italic> allele carriers [<xref rid="pone.0165631.ref022" ref-type="bibr">22</xref>], the <italic>CYP3A5</italic> genetic polymorphism may be therefore the most important genetic contributor not only to interindividual but also to interracial differences in CYP3A-dependent drug clearance.</p><p>Therefore, the aim of this study was to assess the impact of the loss-of-function <italic>CYP3A5*3</italic> allele on DRV plasma concentrations in HIV-1 infected patients co-treated or not with ETR.</p></sec><sec sec-type="materials|methods" id="sec006"><title>Materials and Methods</title><p>This study was conducted at the AIDS Reference center of Cliniques universitaires Saint-Luc in Brussels, Belgium. HIV-1 infected patients of 18 years and older treated by DRV/r for at least one month prior to inclusion were eligible for the study and recruited between November 2012 and June 2015. The study protocol (NCT02514369) was approved by the Ethical Committee of UCL Saint-Luc: "Comit&#x000e9; d'Ethique hospitalo-facultaire" (National number: B403; approval: B403201214460). All patients included provided their written informed consent to participate to the study. In total, 149 HIV-1 infected patients were recruited.</p><p>After a clinical assessment and in addition to the samples routinely collected for the clinical follow-up (viral load, CD4 cell count), two more blood samples were drawn immediately before drug intake, with the highest timing precision conceivable given the ambulatory context of the study recruitment. These samples were used for determination of DRV plasma through concentration ([DRV]<sub>plasma</sub>) and for genomic DNA isolation, respectively. In order to obtain a post-intake delay as close as possible to the trough sampling time, each patient was personally contacted by phone a few days before the study visit to ensure not taking the medication prior to blood sampling.</p><p>To quantify [DRV]<sub>plasma</sub>, blood samples were obtained on heparinized tubes and immediately centrifuged at 1125x<italic>g</italic> for 10min at room temperature (RT). Plasma was then collected and stored at -20&#x000b0;C until the day of quantification.</p><p>The [DRV]<sub>plasma</sub> was measured using an ultra performance liquid chromatography (UPLC) method with diode array detection (DAD)[<xref rid="pone.0165631.ref028" ref-type="bibr">28</xref>] based on a method routinely used in our laboratory. Using this validated method, the laboratory has obtained successful results in the external quality control program organized by SKML (The Netherlands) on antiretroviral drugs, including DRV.</p><p>The second blood sample was drawn in an EDTA tube and stored at -20&#x000b0;C until the day of genotyping analysis. Genomic DNA was extracted from whole blood using a QIAamp&#x000ae; DNA Mini Kit <sup>TM</sup> (Qiagen, CA, USA). Allelic discrimination for the determination of <italic>CYP3A5</italic> 6986A &#x0003e; G was performed using real time PCR TaqMan&#x000ae; (Applied Biosystems, CA, USA) genotyping assay (C_26201809_30) on the StepOnePlus <sup>TM</sup> Real Time PCR System (Applied biosystems, CA, USA).</p><p>[DRV]<sub>plasma</sub> were log-transformed for normalization of the distribution before further analysis. They were then reported as geometric mean of plasmatic DRV concentration (mean [DRV]<sub>plasma</sub>). Genotype and allele frequencies were calculated and deviations from Hardy-Weinberg equilibrium (HWE) were evaluated using exact tests.</p><p>The patients were also classified into CYP3A5 expressors (<italic>CYP3A5*1</italic> allele carriers) and CYP3A5 non-expressors (<italic>CYP3A5*3</italic> homozygous).</p><p>Subsequently, the associations between [DRV]<sub>plasma</sub> and CYP3A5 genotype-based expression status were analyzed both in the entire cohort and in the subgroup of patients with or without co-administration DRV-ETR.</p><p>Statistical analyses were performed using JMP Pro 12 version 12.0.1 for MAC (SAS Institute Inc., Cary, NC, USA).</p><p>The comparison of the [DRV]<sub>plasma</sub> with the different CYP3A5 groups was performed using the two-tailed Mann-Whitney <italic>U</italic> test. A p-value &#x0003c; 0.05 was deemed statistically significant.</p></sec><sec sec-type="results" id="sec007"><title>Results</title><p>Fourteen out of the 149 patients were excluded because of suspected non-compliance (n = 6) or non-classical DRV dosage (DRV 600mg QD, DRV 900mg QD, DRV 1200mg QD) (n = 7), while one patient was excluded because of substantial deviation from the drug intake protocol (DRV intake just before blood sampling). The clinical characteristics of the 135 remaining patients are reported in <xref rid="pone.0165631.t001" ref-type="table">Table 1</xref>.</p><table-wrap id="pone.0165631.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0165631.t001</object-id><label>Table 1</label><caption><title>Patients characteristics at day of sampling.</title></caption><alternatives><graphic id="pone.0165631.t001g" xlink:href="pone.0165631.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" style="border-bottom:thick;border-top:thick" rowspan="1" colspan="1">Number of patients included</th><th align="left" style="border-bottom:thick;border-top:thick" rowspan="1" colspan="1">135</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">DRV dosage repartition, n (%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="border-bottom:thick" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02022; 800mg once daily&#x000a0;&#x000a0;&#x000a0;&#x000a0;<break/> &#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02022; 600mg twice daily</td><td align="left" style="border-bottom:thick" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02022; 93 (69%)<break/> &#x000a0;&#x000a0;&#x000a0;&#x000a0; &#x02022; 42 (31%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Co-administered ARV drugs</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02022; NNRTI</td><td align="left" rowspan="1" colspan="1">ETR (n = 16) NVP (n = 2) NNRTI-free (n = 117)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02022; NRTI</td><td align="left" rowspan="1" colspan="1">ABC/3TC (n = 21),FTC/TDF (= 67), 3TC (n = 16), TDF245mg (n = 8), NRTI-free (n = 25)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02022; INSTI</td><td align="left" rowspan="1" colspan="1">RAL (n = 38), DTG (n = 4)</td></tr><tr><td align="left" style="border-bottom:thick" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02022; MVC</td><td align="left" style="border-bottom:thick" rowspan="1" colspan="1">n = 13</td></tr><tr><td align="left" style="border-bottom:thick" rowspan="1" colspan="1">Age, years (mean &#x000b1; SD)</td><td align="left" style="border-bottom:thick" rowspan="1" colspan="1">48 &#x000b1; 12.4</td></tr><tr><td align="left" style="border-bottom:thick" rowspan="1" colspan="1">Body Mass Index, kg/m<sup>2</sup> (mean &#x000b1; SD)</td><td align="left" style="border-bottom:thick" rowspan="1" colspan="1">25.4 &#x000b1; 4.9</td></tr><tr><td align="left" style="border-bottom:thick" rowspan="1" colspan="1">Gender&#x000a0;, n (%), male</td><td align="left" style="border-bottom:thick" rowspan="1" colspan="1">86 (64%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Ethnic origin, n (%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02022; Caucasian</td><td align="left" rowspan="1" colspan="1">85 63%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02022; African</td><td align="left" rowspan="1" colspan="1">49 36%)</td></tr><tr><td align="left" style="border-bottom:thick" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02022; South American</td><td align="left" style="border-bottom:thick" rowspan="1" colspan="1">1 (1%)</td></tr><tr><td align="left" style="border-bottom:thick" rowspan="1" colspan="1">CD4 cell count, cells per &#x003bc;l (median [min-max])</td><td align="left" style="border-bottom:thick" rowspan="1" colspan="1">532 [33&#x02013;1641]</td></tr><tr><td align="left" style="border-bottom:thick" rowspan="1" colspan="1">Nadir CD4 cell count, cells per &#x003bc;l (median [min-max])</td><td align="left" style="border-bottom:thick" rowspan="1" colspan="1">149 [2&#x02013;681]</td></tr><tr><td align="left" style="border-bottom:thick" rowspan="1" colspan="1">HIV-1 RNA &#x0003c; 37 copies per mL, n (%)</td><td align="left" style="border-bottom:thick" rowspan="1" colspan="1">103 6%)</td></tr><tr><td align="left" style="border-bottom:thick" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02022; HIV-1 RNA &#x0003e; 37 copies per mL, n(%)<break/> &#x000a0;&#x000a0;&#x000a0;&#x000a0; &#x02022; copies per mL (median [min-max])</td><td align="left" style="border-bottom:thick" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02022; 32 (24%)<break/> &#x000a0;&#x000a0;&#x000a0;&#x000a0; &#x02022; 96 [37&#x02013;1687]</td></tr><tr><td align="left" style="border-bottom:thick" rowspan="1" colspan="1">Duration of treatment, months (mean &#x000b1; SD)</td><td align="left" style="border-bottom:thick" rowspan="1" colspan="1">24.9 &#x000b1; 22.8</td></tr><tr><td align="left" rowspan="1" colspan="1">Post-intake delay, hours (mean [CI95%])</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02022; DRV/r 800/100mg once daily</td><td align="left" rowspan="1" colspan="1">20.0 [18.7&#x02013;21.4]</td></tr><tr><td align="left" style="border-bottom:thick" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02022; DRV/r 600/100mg twice daily</td><td align="left" style="border-bottom:thick" rowspan="1" colspan="1">14,5 [13.5&#x02013;15.1]</td></tr><tr><td align="left" style="border-bottom:thick" rowspan="1" colspan="1">eGFR, mL/min/1,73m<sup>2</sup> (mean &#x000b1; SD)</td><td align="left" style="border-bottom:thick" rowspan="1" colspan="1">79.6 &#x000b1; 16.2</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t001fn001"><p>DRV: Darunavir, ARV: antiretroviral, NNRTI: Non-Nucleoside Reverse Transcriptase Inhibitor, NRTI: Nucleoside Reverse Transcriptase Inhibitor, INSTI: Integrase Strand Transfer Inhibitor, RAL: raltegravir, DTG: dolutegravir, MVC: maraviroc ETR: etravirine, NVP: nevirapine, ABC: abacavir, 3TC: lamivudine, FTC: emtricitabine, TDF: tenofovir disoproxil fumarate, NNRTI-free: without any NNRTI, NRTI-free: without any NRTI, eGFR: estimated glomerular filtration rate by utilizing the Modification of Diet in Renal Disease (MDRD) study equation</p></fn></table-wrap-foot></table-wrap><p>Sixteen out of the 135 included patients (86 (64%) male, mean age 48 &#x000b1; 12.4 years) received a regimen comprising DRV/r and ETR (200mg BID) in co-administration with 13 of these patients receiving DRV/r at the 600/100mg twice daily regimen.</p><p>In terms of ethnic origin, 85 (63%) patients were Caucasian, 49 (36%) were African and one patient originated from South-America.</p><p>The mean duration of the treatment was 24.9 &#x000b1; 22.8 months. 103 (76%) patients had an undetectable viral load (&#x0003c; 37 cps/ml) and among the remaining 32 patients, the median plasma HIV-RNA level was 96 cps/ml [min-max: 37&#x02013;1687].</p><p>Among the 135 patients, 45% were classified as CYPA5 expressors (<italic>CYP3A5*1/*1</italic> and <italic>*1/*3</italic>) (<xref rid="pone.0165631.t002" ref-type="table">Table 2</xref>). Considering the subgroup of the 16 patients receiving DRV combined with ETR, 50% were CYPA5 expressors. The <italic>CYP3A5*1</italic> allele frequencies were 77.6% and 9.4% in African and Caucasian patients, respectively. The <italic>CYP3A5</italic> genotype distributions were conformed to Hardy-Weinberg equilibrium.</p><table-wrap id="pone.0165631.t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0165631.t002</object-id><label>Table 2</label><caption><title>Distribution of the <italic>CYP3A5</italic> genotypes in the study cohort and according to the ethnicity (Caucasian versus African origin).</title></caption><alternatives><graphic id="pone.0165631.t002g" xlink:href="pone.0165631.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Study Cohort</th><th align="left" rowspan="1" colspan="1">Caucasian</th><th align="left" rowspan="1" colspan="1">African</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><italic>CYP3A5*3/*3</italic></td><td align="left" rowspan="1" colspan="1">CYP3A5 non expressors</td><td align="left" rowspan="1" colspan="1">75 (55%)</td><td align="left" rowspan="1" colspan="1">70 (82.5%)</td><td align="left" rowspan="1" colspan="1">4 (8%)</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>CYP3A5*1/*3</italic></td><td align="left" rowspan="2" colspan="1">CYP3A5 expressors</td><td align="left" rowspan="1" colspan="1">28 (21%)</td><td align="left" rowspan="1" colspan="1">14 (16.5%)</td><td align="left" rowspan="1" colspan="1">14 (29%)</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>CYP3A5*1/*1</italic></td><td align="left" rowspan="1" colspan="1">32 (24%)</td><td align="left" rowspan="1" colspan="1">1 (1%)</td><td align="left" rowspan="1" colspan="1">31 (63%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Total</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">135</td><td align="left" rowspan="1" colspan="1">85</td><td align="left" rowspan="1" colspan="1">49</td></tr></tbody></table></alternatives></table-wrap><p>Overall, mean [DRV]<sub>plasma</sub> was 1805ng/ml [CI95%: 1593&#x02013;2045]. There was no statistically significant correlation between age, gender, ethnicity, weight and [DRV]<sub>plasma.</sub></p><p>When considering the entire cohort, CYP3A5 allelic status did not significantly influence mean [DRV]<sub>plasma</sub> with values of 1894ng/ml [CI95%: 1566&#x02013;2290] and 1737ng/ml [CI95%: 1468&#x02013;2057] for CYP3A5 expressors and CYP3A5 non-expressors, respectively (p = 0.43) (<xref rid="pone.0165631.t003" ref-type="table">Table 3</xref>).</p><table-wrap id="pone.0165631.t003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0165631.t003</object-id><label>Table 3</label><caption><title>DRV plasma concentration according to <italic>CYP3A5*3</italic> polymorphism.</title></caption><alternatives><graphic id="pone.0165631.t003g" xlink:href="pone.0165631.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" style="border-bottom:thick" rowspan="1" colspan="1"/><th align="left" style="border-bottom:thick" rowspan="1" colspan="1">CYP3A5 non-expressors</th><th align="left" style="border-bottom:thick" rowspan="1" colspan="1">CYP3A5 expressors</th><th align="left" style="border-bottom:thick" rowspan="1" colspan="1">P-value</th></tr></thead><tbody><tr><td align="left" style="border-bottom:thick" rowspan="1" colspan="1">&#x02022; Study cohort<break/> &#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02022; n = 135</td><td align="left" style="border-bottom:thick" rowspan="1" colspan="1">&#x02022; 1737ng/ml<break/> &#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02022; (CI95%: 1468&#x02013;2057)<break/> &#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02022; n = 75</td><td align="left" style="border-bottom:thick" rowspan="1" colspan="1">&#x02022; 1894ng/ml<break/> &#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02022; (CI95%:1566&#x02013;2290)<break/> &#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02022; n = 60</td><td align="left" style="border-bottom:thick" rowspan="1" colspan="1">0.43</td></tr><tr><td align="left" style="border-bottom:thick" rowspan="1" colspan="1">&#x02022; Subgroup DRV/r 800/100mg QD<break/> &#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02022; n = 93</td><td align="left" style="border-bottom:thick" rowspan="1" colspan="1">&#x02022; 1498ng/ml<break/> &#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02022; (CI95%: 1227&#x02013;1828)<break/> &#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02022; n = 52</td><td align="left" style="border-bottom:thick" rowspan="1" colspan="1">&#x02022; 1693ng/ml<break/> &#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02022; (CI95%:1314&#x02013;2182)<break/> &#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02022; n = 41</td><td align="left" style="border-bottom:thick" rowspan="1" colspan="1">0.34</td></tr><tr><td align="left" style="border-bottom:thick" rowspan="1" colspan="1">&#x02022; Subgroup DRV/r 600/100mg BID<break/> &#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02022; n = 42</td><td align="left" style="border-bottom:thick" rowspan="1" colspan="1">&#x02022; 2430<break/> &#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02022; (CI95%: 1817&#x02013;3249)<break/> &#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02022; n = 23</td><td align="left" style="border-bottom:thick" rowspan="1" colspan="1">&#x02022; 2411<break/> &#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02022; (CI95%: 1895&#x02013;3067)<break/> &#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02022; n = 19</td><td align="left" style="border-bottom:thick" rowspan="1" colspan="1">0.92</td></tr><tr><td align="left" style="border-bottom:thick" rowspan="1" colspan="1">&#x02022; Patients without ETR<break/> &#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02022; n = 119</td><td align="left" style="border-bottom:thick" rowspan="1" colspan="1">&#x02022; 1619ng/ml<break/> &#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02022; (CI95%: 1356&#x02013;1932)<break/> &#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02022; n = 67</td><td align="left" style="border-bottom:thick" rowspan="1" colspan="1">&#x02022; 1987ng/ml<break/> &#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02022; (CI95%: 1611&#x02013;2451)<break/> &#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02022; n = 52</td><td align="left" style="border-bottom:thick" rowspan="1" colspan="1">0.07</td></tr><tr><td align="left" style="border-bottom:thick" rowspan="1" colspan="1">&#x02022; Subgroup DRV/r plus ETR<break/> &#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02022; n = 16</td><td align="left" style="border-bottom:thick" rowspan="1" colspan="1">&#x02022; 3141ng/ml<break/> &#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02022; (CI95%: 2042&#x02013;4831)<break/> &#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02022; n = 8</td><td align="left" style="border-bottom:thick" rowspan="1" colspan="1">&#x02022; 1385ng/ml<break/> &#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02022; (CI95%:886.3&#x02013;2165)<break/> &#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02022; n = 8</td><td align="left" style="border-bottom:thick" rowspan="1" colspan="1">0.007</td></tr><tr><td align="left" style="border-bottom:thick" rowspan="1" colspan="1">&#x02022; Subgroup DRV/r 600/100mg BID plus ETR<break/> &#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02022; n = 13</td><td align="left" style="border-bottom:thick" rowspan="1" colspan="1">&#x02022; 3141ng/ml<break/> &#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02022; (CI95%: 2042&#x02013;4831)<break/> &#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02022; n = 8</td><td align="left" style="border-bottom:thick" rowspan="1" colspan="1">&#x02022; 1486ng/ml<break/> &#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02022; (CI95%:725&#x02013;3044)<break/> &#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02022; n = 5</td><td align="left" style="border-bottom:thick" rowspan="1" colspan="1">0.034</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t003fn001"><p>DRV plasma concentrations are expressed as geometric mean and geometric 95% confidence interval (CI95%)</p></fn></table-wrap-foot></table-wrap><p>However, when analyzing the data for the 16 patients receiving ETR in co-administration with DRV, significantly lower mean [DRV]<sub>plasma</sub> were observed for CYP3A5 expressors when compared to non-expressors (1385ng/ml [CI95%:886.3&#x02013;2165] versus 3141ng/ml [CI95%:2042&#x02013;4831], p = 0.007) (<xref ref-type="fig" rid="pone.0165631.g001">Fig 1</xref> and <xref rid="pone.0165631.t003" ref-type="table">Table 3</xref>). This difference was also significant in the subgroup of the 13 patients receiving exactly the same DRV and ETR regimen.</p><fig id="pone.0165631.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0165631.g001</object-id><label>Fig 1</label><caption><title>Darunavir plasma concentration according to <italic>CYP3A5*3</italic> polymorphism in patients co-treated with darunavir and etravirine.</title><p>Values are reported on the Y-axis using a box and whisker plot. Bottom and top of the boxes indicate the 25th and 75th percentiles, respectively and the inside-line represents the 50th percentile (median). Whiskers show maximal and minimal observed values.</p></caption><graphic xlink:href="pone.0165631.g001"/></fig><p>For the 119 patients without ETR co-administration, CYP3A5 allelic status did not significantly influence mean [DRV]<sub>plasma</sub> with values of 1987ng/ml [CI95%: 1611&#x02013;2451] and 1619ng/ml [CI95%: 1356&#x02013;1932] for CYP3A5 expressors and CYP3A5 non-expressors, respectively (p = 0.07). (<xref rid="pone.0165631.t003" ref-type="table">Table 3</xref>).</p></sec><sec sec-type="conclusions" id="sec008"><title>Discussion</title><p>In our study, we showed that [DRV]<sub>plasma</sub> was significantly lower in the CYP3A5 expressor than in the non-expressor group when ETR is co-administered suggesting a specific ETR-driven CYP3A5 induction but only in CYP3A5 expressors.</p><p>Drug-drug interactions between antiretroviral drugs are complex and this aspect remains a challenge for most clinicians.</p><p>As ETR is an inducer of CYP3A, and an inhibitor of CYP2C9, CYP2C19 and P-gp, we could expect that its co-administration with drugs that are substrates of these drug-metabolizing enzymes and/or drug transporters may alter their PK profile. Indeed, drug-drug interactions have been demonstrated between ETR and other antiretroviral agents that are substrates of CYP3A. As an example, Kakuda et al. demonstrated that co-administration of ETR with maraviroc in 14 healthy predominantly Caucasian (93%) adults, decreased maraviroc exposure by 53% (AUC<sub>0&#x02013;12h</sub>). As maraviroc is mainly eliminated following CYP3A4 biotransformation, this observation would suggest a significant CYP3A induction mediated by ETR [<xref rid="pone.0165631.ref029" ref-type="bibr">29</xref>]. Interactions with ETR have also been described with PI such as atazanavir (ATV), which is also a CYP3A substrate. Indeed, it was shown in an open-label crossover study conducted in 32 healthy volunteers that when ETR was co-administrated with unboosted ATV (400mg QD, n = 16, 38% Caucasian, 19% Black, 44% Hispanic) or with boosted ATV/r (300/100mg QD, n = 16, 63% Caucasian, 19% Black, 19% Hispanic), ATV trough concentration was decreased by 38 and 47% with or without ritonavir, respectively [<xref rid="pone.0165631.ref030" ref-type="bibr">30</xref>]. The effects observed in the latter two studies could be due to an induction of CYP3A enzymes by ETR.</p><p>We have previously demonstrated a possible interaction between DRV and ETR with ETR co-administration decreasing [DRV]<sub>plasma</sub> by approximately 50% [<xref rid="pone.0165631.ref031" ref-type="bibr">31</xref>]. It was the first time that such an interaction was described between both drugs and this data suggested a potential induction of CYP3A isoforms by ETR.</p><p>The conclusion of the absence of major interaction between DRV and ETR, as mentioned in the prescribing information of DRV[<xref rid="pone.0165631.ref006" ref-type="bibr">6</xref>] or ETR[<xref rid="pone.0165631.ref015" ref-type="bibr">15</xref>], is mainly based on pharmacokinetic substudies of the phase 3 trials DUET-1 and DUET-2 whereas DRV/r 600/100 mg bid was included in the background regimen of patients with ETR. Noteworthy is the fact that the majority of the patients receiving ETR in these phase 3 trials were of Caucasian origin (65% and 77% in DUET-1 and DUET-2, respectively) with an expected low prevalence of CYP3A5 expressors while only few of them were of Black origin (14% and 13% in DUET-1 and DUET-2, respectively)[<xref rid="pone.0165631.ref013" ref-type="bibr">13</xref>, <xref rid="pone.0165631.ref014" ref-type="bibr">14</xref>]. Four other studies (as detailed below) [<xref rid="pone.0165631.ref032" ref-type="bibr">32</xref>&#x02013;<xref rid="pone.0165631.ref035" ref-type="bibr">35</xref>] concluded that no dose adjustments were required when DRV and ETR were co-administered.</p><p>In the phase I, open-label, randomized, two-way crossover study of Sch&#x000f6;ller-Gy&#x000fc;re et al involving 32 healthy volunteers, it was observed that co-administration of DRV/r (600/100mg bid) with ETR (100mg or 200mg bid) resulted in unchanged DRV PK parameters (in particular similar C<sub>trough</sub> and C<sub>max</sub>) with the exception of a slight 15% increase in mean DRV AUC<sub>0&#x02013;12h</sub> when combined with ETR 200mg bid compared to DRV alone [<xref rid="pone.0165631.ref032" ref-type="bibr">32</xref>]. Conversely, co-administration of DRV/r with ETR 100mg twice daily decreased ETR exposure by 37% when compared to ETR alone, which might reflect the inductive effect of CYP2C9 and CYP2C19 isoforms by ritonavir [<xref rid="pone.0165631.ref036" ref-type="bibr">36</xref>]. However, in this cohort of Sch&#x000f6;ller-Gy&#x000fc;re et al, 94% of the patients were of Caucasian origin, and no African volunteers were included. The situation was clearly different in our cohort, where 36% of the patients were of African origin with a higher probability of CYP3A5 expression, as explained above. In addition, in their study, out of the 32 volunteers, only 23 completed the trial, which greatly reduced the power of the statistical analysis (13 and 10 in the group ETR 100mg bid and 200mg bid, respectively).</p><p>The study of Boffito et al. included 10 HIV-1 infected patients receiving DRV/r (600/100mg bid) combined with ETR (200mg bid) that were mostly Caucasians (7 out of 10)[<xref rid="pone.0165631.ref033" ref-type="bibr">33</xref>]. In that particular study, the authors demonstrated that DRV exposure was similar to &#x0201c;historical control&#x0201d; (obtained from subjects taking either ETR without DRV or DRV in the absence of ETR) [<xref rid="pone.0165631.ref033" ref-type="bibr">33</xref>].</p><p>Later, Barrail-Tran et al. studied the interaction between DRV/r (600/100mg bid) or raltegravir (RAL, 400mg bid) and ETR (200mg bid) on a small group of 10 HIV-1 infected patients with previous multiple treatment failure [<xref rid="pone.0165631.ref034" ref-type="bibr">34</xref>]. Surprisingly, the addition of ETR leaded to an increase of DRV C<sub>trough</sub> and AUC by 71% (from 2241ng/ml to 3837ng/ml) and 14%, respectively. Unfortunately, no data was available concerning the ethnic origin of the patients. All these patients were heavily pretreated prior to enrollment with other ARV drugs including drug-metabolizing enzymes and/or transporter inhibitors or inducers. Therefore it remains unknown if the increase in DRV exposure after the addition of ETR in this study was due to ETR or to the effect of the concomitant ARV drugs.</p><p>The only cohort involving a large proportion of Black people was conducted by Kakuda et al. [<xref rid="pone.0165631.ref035" ref-type="bibr">35</xref>]. This multicenter study included 376 patients among whom 190 co-treated with DRV/r (600mg/100mg bid) and ETR (200mg bid) (60% Black, 22% Hispanic, 17% white and 1% Asian or other). They demonstrated that pharmacokinetic exposure to DRV was not influenced by race, sex, age, body weight or use of ETR or TDV but, as pinpointed by the authors themselves, this study was &#x0201c;not specifically powered to compare the effects of these covariates on DRV PK&#x0201d;.</p><p>In our study, we have highlighted a significant impact of the <italic>CYP3A5</italic> polymorphism on the PK interaction between DRV and ETR. In contrast to our results, the majority of the above described studies concluded to no clinically relevant interaction between DRV and ETR. However, all these studies were performed either predominantly on subjects of Caucasian origin with only a small proportion of African or Afro-American subjects [<xref rid="pone.0165631.ref032" ref-type="bibr">32</xref>&#x02013;<xref rid="pone.0165631.ref034" ref-type="bibr">34</xref>] or without stratification allowing to test the effect of ethnicity/CYP3A5 expression in the sub-group of patients co-treated by DRV and ETR [<xref rid="pone.0165631.ref032" ref-type="bibr">32</xref>&#x02013;<xref rid="pone.0165631.ref035" ref-type="bibr">35</xref>]. The frequency of <italic>CYP3A5*1</italic> carriers (CYP3A5 expressors) is indeed very low in Caucasians contrasting with the high frequency reported among Africans who are predominantly CYP3A5 expressors (73%). When expressed, CYP3A5 can represent more than 50% of the total hepatic CYP3A content[<xref rid="pone.0165631.ref022" ref-type="bibr">22</xref>]. With this in mind, it might be one of the most important genetic contributors to interindividual and interracial differences in CYP3A-dependent drug metabolism.</p><p>In the 16 patients in our study treated by DRV combined with ETR, 6 were of African origin (38%), and all were classified as CYP3A5 expressors based on their genotype. This frequency is presumably much higher than in previous cited studies [<xref rid="pone.0165631.ref013" ref-type="bibr">13</xref>, <xref rid="pone.0165631.ref014" ref-type="bibr">14</xref>, <xref rid="pone.0165631.ref032" ref-type="bibr">32</xref>, <xref rid="pone.0165631.ref033" ref-type="bibr">33</xref>]. The 10 other ETR/DVR/r patients were of Caucasian origin, including 8 CYP3A5 non-expressors. Given that in CYP3A5 expressors, CYP3A5 is the predominant CYP3A isoenzyme, one can hypothesize that, in this particular population, CYP3A5 influences the DRV metabolism maybe more than other CYP3A isoforms, i.e. CYP3A4. The fact that no difference was observed in [DRV]<sub>plasma</sub> between CYP3A5 expressors and non-expressors in the overall study population (n = 135) or in the subgroup receiving only DRV/r without ETR (n = 119) could be partly explained by the CYP3A inhibition by RTV. Such an effect has been previously reported for saquinavir (SQV) with significant difference observed between <italic>CYP3A5</italic> genotype with the unboosted regimen on one hand [<xref rid="pone.0165631.ref037" ref-type="bibr">37</xref>] and no difference with the boosted SQV/r regimen[<xref rid="pone.0165631.ref038" ref-type="bibr">38</xref>]. Therefore, the CYP3A induction by ETR could partly compensate its inhibition by RTV making the effect of <italic>CYP3A5</italic> genotype visible. Although not supported by our experimental data, a similar effect could be theoretically expected in patients treated with cobicistat, a more recent DRV booster.</p><p>In the sub-group of patients co-treated with DRV/r and ETR, the mean [DRV]<sub>plasma</sub> was 1385ng/ml [IC95%:930.7&#x02013;2062] for CYP3A5 expressors. This value is below the recommended consensus for treatment-experienced patients which is between 1800 and 2000 ng/ml[<xref rid="pone.0165631.ref039" ref-type="bibr">39</xref>]. Surprisingly, neither the prescribing information of DRV or ETR [<xref rid="pone.0165631.ref006" ref-type="bibr">6</xref>, <xref rid="pone.0165631.ref015" ref-type="bibr">15</xref>] nor the consensus website <ext-link ext-link-type="uri" xlink:href="http://www.hiv-druginteractions.org/">www.hiv-druginteractions.org</ext-link> (University of Liverpool) mention any caution when DRV is combined with ETR particularly in patients more difficult to treat with multidrug resistant virus and limited therapeutic options.</p><p>Among these 16 patients receiving DRV/r and ETR, only one had a detectable viral load (110 copies/mL at day of inclusion, undetectable 6 months after but with 3 blips during the 2 years of follow-up). This particular case was a woman of African origin, CYP3A5 expressor with a low [DRV]<sub>plasma</sub> at 652 ng/ml.</p><p>This potentially reflects a modest clinical consequence of this low DRV exposure in CYP3A5 expressors but it is important to stress that all these 16 patients were heavily treated and maybe then &#x0201c;protected&#x0201d; against a virological rebound by the other associated ARV drugs (robust backbone). Nonetheless, sub-optimal drug exposure increases the likelihood of viral rebound resistance and may confer resistance to the drugs in the current regimen and/or cross-resistance to other drugs of the same class by decrease drug pressure. So, knowing that a drug-drug interaction in a determined population (CYP3A5 expressors) may decrease a plasma drug concentration by more than 55% remains useful information, in our opinion, particularly in patients with limited options treatment and/or with suboptimal backbone.</p><p>The present study has however some limitations. First, our cohort of patients co-treated with DRV and ETR is still quite small, although bigger than most of previous published studies. Then, this drug-drug interaction mediated by a genetic polymorphism should be studied in a larger cohort to evaluate its potential clinical impact.</p><p>Secondly, the dosage of the C<sub>trough</sub> as unique DRV PK parameter probably does not reflect the daily drug exposure as best as full AUC determination. However, as this (preliminary) study was performed in real life with ambulatory patients, the C<sub>trough</sub> was the only parameter that we could obtain. Furthermore, C<sub>trough</sub> represents the only parameter useful and available in daily practice. Moreover, therapeutic drug monitoring (TDM) based on drug trough plasma concentrations has shown its efficacy and has been successfully applied in clinical settings to optimize HIV treatment management by improving efficacy and reducing toxicity in particular scenarios such as pregnancy with risk factors for virologic failure, and drug-drug interaction [<xref rid="pone.0165631.ref040" ref-type="bibr">40</xref>]. So, this one-time point measurement remains a suitable parameter to evaluate DRV exposure and reflects quite rationally real life in clinical practice settings.</p></sec><sec sec-type="conclusions" id="sec009"><title>Conclusions</title><p>ETR seems to boost DRV elimination but only significantly among CYP3A5 expressors, suggesting a specific CYP3A5 activation. Our study has highlighted that CYP3A5 expressors might be more at risk of infra-therapeutic DRV plasma concentrations when ETR is included in their therapeutic regimen. Knowing that the majority of people of African origin are CYP3A5 expressors, this observation may be clinically relevant in this population at risk of being under the therapeutic range, especially in patients with limited drug options and/or unable to take integrase strand transfer inhibitor (INSTI).</p><p>This result is a good illustration of a genotype-based drug interaction that could have also considerable consequences if translated to other CYP3A5-metabolized drugs. More generally, this information could help physicians to understand the relationship between ethnic origin and predisposition to drug response in order to improve therapies.</p><p>Further investigations are thus needed to confirm this association and to explore its clinical impact before recommending systematic <italic>CYP3A5</italic> pre-emptive genotyping. We believe it may be wise to modify the current prescribing information of DRV and ETR [<xref rid="pone.0165631.ref006" ref-type="bibr">6</xref>, <xref rid="pone.0165631.ref015" ref-type="bibr">15</xref>] and/or the consensus website <ext-link ext-link-type="uri" xlink:href="http://www.hiv-druginteractions.org/">www.hiv-druginteractions.org</ext-link> (University of Liverpool) to advise caution when DRV is combined with ETR in this particular setting.</p></sec></body><back><ack><p>The authors would like to thank the patients for their participation in the trial.</p></ack><ref-list><title>References</title><ref id="pone.0165631.ref001"><label>1</label><mixed-citation publication-type="journal"><name><surname>Deeks</surname><given-names>ED</given-names></name>. <article-title>Darunavir: a review of its use in the management of HIV-1 infection</article-title>. <source>Drugs</source>. <year>2014</year>;<volume>74</volume>(<issue>1</issue>):<fpage>99</fpage>&#x02013;<lpage>125</lpage>. <pub-id pub-id-type="doi">10.1007/s40265-013-0159-3</pub-id> .<pub-id pub-id-type="pmid">24338166</pub-id></mixed-citation></ref><ref id="pone.0165631.ref002"><label>2</label><mixed-citation publication-type="journal"><name><surname>McKeage</surname><given-names>K</given-names></name>, <name><surname>Perry</surname><given-names>CM</given-names></name>, <name><surname>Keam</surname><given-names>SJ</given-names></name>. <article-title>Darunavir: a review of its use in the management of HIV infection in adults</article-title>. <source>Drugs</source>. <year>2009</year>;<volume>69</volume>(<issue>4</issue>):<fpage>477</fpage>&#x02013;<lpage>503</lpage>. <pub-id pub-id-type="doi">10.2165/00003495-200969040-00007</pub-id> .<pub-id pub-id-type="pmid">19323590</pub-id></mixed-citation></ref><ref id="pone.0165631.ref003"><label>3</label><mixed-citation publication-type="journal"><name><surname>Katlama</surname><given-names>C</given-names></name>, <name><surname>Esposito</surname><given-names>R</given-names></name>, <name><surname>Gatell</surname><given-names>JM</given-names></name>, <name><surname>Goffard</surname><given-names>JC</given-names></name>, <name><surname>Grinsztejn</surname><given-names>B</given-names></name>, <name><surname>Pozniak</surname><given-names>A</given-names></name>, <etal>et al</etal>
<article-title>Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1</article-title>. <source>Aids</source>. <year>2007</year>;<volume>21</volume>(<issue>4</issue>):<fpage>395</fpage>&#x02013;<lpage>402</lpage>. <pub-id pub-id-type="doi">10.1097/QAD.0b013e328013d9d7</pub-id> .<pub-id pub-id-type="pmid">17301557</pub-id></mixed-citation></ref><ref id="pone.0165631.ref004"><label>4</label><mixed-citation publication-type="journal"><name><surname>Rittweger</surname><given-names>M</given-names></name>, <name><surname>Arasteh</surname><given-names>K</given-names></name>. <article-title>Clinical pharmacokinetics of darunavir</article-title>. <source>Clin Pharmacokinet</source>. <year>2007</year>;<volume>46</volume>(<issue>9</issue>):<fpage>739</fpage>&#x02013;<lpage>56</lpage>. Epub 2007/08/24. <pub-id pub-id-type="doi">10.2165/00003088-200746090-00002</pub-id><pub-id pub-id-type="pmid">17713972</pub-id></mixed-citation></ref><ref id="pone.0165631.ref005"><label>5</label><mixed-citation publication-type="journal"><name><surname>De Meyer</surname><given-names>S</given-names></name>, <name><surname>Azijn</surname><given-names>H</given-names></name>, <name><surname>Surleraux</surname><given-names>D</given-names></name>, <name><surname>Jochmans</surname><given-names>D</given-names></name>, <name><surname>Tahri</surname><given-names>A</given-names></name>, <name><surname>Pauwels</surname><given-names>R</given-names></name>, <etal>et al</etal>
<article-title>TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2005</year>;<volume>49</volume>(<issue>6</issue>):<fpage>2314</fpage>&#x02013;<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.49.6.2314-2321.2005</pub-id>
<pub-id pub-id-type="pmid">15917527</pub-id></mixed-citation></ref><ref id="pone.0165631.ref006"><label>6</label><mixed-citation publication-type="other">Prezista&#x02122; (darunavir), prescribing information. Janssen Pharmaceuticals, Inc. 2006 revised in May 2015. Available: <ext-link ext-link-type="uri" xlink:href="https://www.prezista.com/sites/default/files/pdf/us_package_insert.pdf">https://www.prezista.com/sites/default/files/pdf/us_package_insert.pdf</ext-link>.</mixed-citation></ref><ref id="pone.0165631.ref007"><label>7</label><mixed-citation publication-type="journal"><name><surname>Clotet</surname><given-names>B</given-names></name>, <name><surname>Bellos</surname><given-names>N</given-names></name>, <name><surname>Molina</surname><given-names>JM</given-names></name>, <name><surname>Cooper</surname><given-names>D</given-names></name>, <name><surname>Goffard</surname><given-names>JC</given-names></name>, <name><surname>Lazzarin</surname><given-names>A</given-names></name>, <etal>et al</etal>
<article-title>Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials</article-title>. <source>Lancet</source>. <year>2007</year>;<volume>369</volume>(<issue>9568</issue>):<fpage>1169</fpage>&#x02013;<lpage>78</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(07)60497-8</pub-id> .<pub-id pub-id-type="pmid">17416261</pub-id></mixed-citation></ref><ref id="pone.0165631.ref008"><label>8</label><mixed-citation publication-type="journal"><name><surname>Mills</surname><given-names>AM</given-names></name>, <name><surname>Nelson</surname><given-names>M</given-names></name>, <name><surname>Jayaweera</surname><given-names>D</given-names></name>, <name><surname>Ruxrungtham</surname><given-names>K</given-names></name>, <name><surname>Cassetti</surname><given-names>I</given-names></name>, <name><surname>Girard</surname><given-names>PM</given-names></name>, <etal>et al</etal>
<article-title>Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis</article-title>. <source>Aids</source>. <year>2009</year>;<volume>23</volume>(<issue>13</issue>):<fpage>1679</fpage>&#x02013;<lpage>88</lpage>. <pub-id pub-id-type="doi">10.1097/QAD.0b013e32832d7350</pub-id> .<pub-id pub-id-type="pmid">19487905</pub-id></mixed-citation></ref><ref id="pone.0165631.ref009"><label>9</label><mixed-citation publication-type="other">Sekar V. S-GS, Lefebvre E., Hoetelmans R. Clinical pharmacology of TMC114 &#x02013;a potent HIV protease inhibitor. AIDS 2006&#x02014;XVI International AIDS Conference: Abstract no TUPE0083. 2006.</mixed-citation></ref><ref id="pone.0165631.ref010"><label>10</label><mixed-citation publication-type="other">Hoetelmans R VdSI, De Pauw M, et al. TMC114, a next generation HIV protease inhibitor: pharmacokinetics and safety following oral administration of multiple doses with and without low doses of ritonavir in healthy volunteers. 10th Conference on Retroviruses and Opportunistic Infections; February 10&#x02013;14, 2003;Boston. Abstract 549.</mixed-citation></ref><ref id="pone.0165631.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>Schiller</surname><given-names>DS</given-names></name>, <name><surname>Youssef-Bessler</surname><given-names>M</given-names></name>. <article-title>Etravirine: a second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) active against NNRTI-resistant strains of HIV</article-title>. <source>Clin Ther</source>. <year>2009</year>;<volume>31</volume>(<issue>4</issue>):<fpage>692</fpage>&#x02013;<lpage>704</lpage>. <pub-id pub-id-type="doi">10.1016/j.clinthera.2009.04.020</pub-id> .<pub-id pub-id-type="pmid">19446143</pub-id></mixed-citation></ref><ref id="pone.0165631.ref012"><label>12</label><mixed-citation publication-type="journal"><name><surname>Andries</surname><given-names>K</given-names></name>, <name><surname>Azijn</surname><given-names>H</given-names></name>, <name><surname>Thielemans</surname><given-names>T</given-names></name>, <name><surname>Ludovici</surname><given-names>D</given-names></name>, <name><surname>Kukla</surname><given-names>M</given-names></name>, <name><surname>Heeres</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title>TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2004</year>;<volume>48</volume>(<issue>12</issue>):<fpage>4680</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.48.12.4680-4686.2004</pub-id>
<pub-id pub-id-type="pmid">15561844</pub-id></mixed-citation></ref><ref id="pone.0165631.ref013"><label>13</label><mixed-citation publication-type="journal"><name><surname>Madruga</surname><given-names>JV</given-names></name>, <name><surname>Cahn</surname><given-names>P</given-names></name>, <name><surname>Grinsztejn</surname><given-names>B</given-names></name>, <name><surname>Haubrich</surname><given-names>R</given-names></name>, <name><surname>Lalezari</surname><given-names>J</given-names></name>, <name><surname>Mills</surname><given-names>A</given-names></name>, <etal>et al</etal>
<article-title>Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial</article-title>. <source>Lancet</source>. <year>2007</year>;<volume>370</volume>(<issue>9581</issue>):<fpage>29</fpage>&#x02013;<lpage>38</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(07)61047-2</pub-id> .<pub-id pub-id-type="pmid">17617270</pub-id></mixed-citation></ref><ref id="pone.0165631.ref014"><label>14</label><mixed-citation publication-type="journal"><name><surname>Lazzarin</surname><given-names>A</given-names></name>, <name><surname>Campbell</surname><given-names>T</given-names></name>, <name><surname>Clotet</surname><given-names>B</given-names></name>, <name><surname>Johnson</surname><given-names>M</given-names></name>, <name><surname>Katlama</surname><given-names>C</given-names></name>, <name><surname>Moll</surname><given-names>A</given-names></name>, <etal>et al</etal>
<article-title>Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial</article-title>. <source>Lancet</source>. <year>2007</year>;<volume>370</volume>(<issue>9581</issue>):<fpage>39</fpage>&#x02013;<lpage>48</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(07)61048-4</pub-id> .<pub-id pub-id-type="pmid">17617271</pub-id></mixed-citation></ref><ref id="pone.0165631.ref015"><label>15</label><mixed-citation publication-type="other">Intelence&#x02122; (etravirine) tablets: full prescribing information. Janssen Pharmaceuticals, Inc. 2008 Revised August 2014. Available: <ext-link ext-link-type="uri" xlink:href="http://www.intelence.com/shared/product/intelence/prescribing-information.pdf">http://www.intelence.com/shared/product/intelence/prescribing-information.pdf</ext-link>.</mixed-citation></ref><ref id="pone.0165631.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>Kakuda</surname><given-names>TN</given-names></name>, <name><surname>Van Solingen-Ristea</surname><given-names>RM</given-names></name>, <name><surname>Onkelinx</surname><given-names>J</given-names></name>, <name><surname>Stevens</surname><given-names>T</given-names></name>, <name><surname>Aharchi</surname><given-names>F</given-names></name>, <name><surname>De Smedt</surname><given-names>G</given-names></name>, <etal>et al</etal>
<article-title>The effect of single- and multiple-dose etravirine on a drug cocktail of representative cytochrome P450 probes and digoxin in healthy subjects</article-title>. <source>Journal of clinical pharmacology</source>. <year>2014</year>;<volume>54</volume>(<issue>4</issue>):<fpage>422</fpage>&#x02013;<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1002/jcph.214</pub-id> .<pub-id pub-id-type="pmid">24165884</pub-id></mixed-citation></ref><ref id="pone.0165631.ref017"><label>17</label><mixed-citation publication-type="journal"><name><surname>Yanakakis</surname><given-names>LJ</given-names></name>, <name><surname>Bumpus</surname><given-names>NN</given-names></name>. <article-title>Biotransformation of the antiretroviral drug etravirine: metabolite identification, reaction phenotyping, and characterization of autoinduction of cytochrome P450-dependent metabolism</article-title>. <source>Drug metabolism and disposition: the biological fate of chemicals</source>. <year>2012</year>;<volume>40</volume>(<issue>4</issue>):<fpage>803</fpage>&#x02013;<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1124/dmd.111.044404</pub-id>
<pub-id pub-id-type="pmid">22269145</pub-id></mixed-citation></ref><ref id="pone.0165631.ref018"><label>18</label><mixed-citation publication-type="other">European Medicines Agency. Intelence tablets: summary of product characteristics (online). Available: <ext-link ext-link-type="uri" xlink:href="http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000900/WC500034180.pdf">http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000900/WC500034180.pdf</ext-link>. 2009 revised May 2016.</mixed-citation></ref><ref id="pone.0165631.ref019"><label>19</label><mixed-citation publication-type="journal"><name><surname>Burk</surname><given-names>O</given-names></name>, <name><surname>Koch</surname><given-names>I</given-names></name>, <name><surname>Raucy</surname><given-names>J</given-names></name>, <name><surname>Hustert</surname><given-names>E</given-names></name>, <name><surname>Eichelbaum</surname><given-names>M</given-names></name>, <name><surname>Brockmoller</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title>The induction of cytochrome P450 3A5 (CYP3A5) in the human liver and intestine is mediated by the xenobiotic sensors pregnane X receptor (PXR) and constitutively activated receptor (CAR)</article-title>. <source>J Biol Chem</source>. <year>2004</year>;<volume>279</volume>(<issue>37</issue>):<fpage>38379</fpage>&#x02013;<lpage>85</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M404949200</pub-id> .<pub-id pub-id-type="pmid">15252010</pub-id></mixed-citation></ref><ref id="pone.0165631.ref020"><label>20</label><mixed-citation publication-type="journal"><name><surname>Thummel</surname><given-names>KE</given-names></name>, <name><surname>Wilkinson</surname><given-names>GR</given-names></name>. <article-title>In vitro and in vivo drug interactions involving human CYP3A</article-title>. <source>Annual review of pharmacology and toxicology</source>. <year>1998</year>;<volume>38</volume>:<fpage>389</fpage>&#x02013;<lpage>430</lpage>. <pub-id pub-id-type="doi">10.1146/annurev.pharmtox.38.1.389</pub-id> .<pub-id pub-id-type="pmid">9597161</pub-id></mixed-citation></ref><ref id="pone.0165631.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>Elens</surname><given-names>L</given-names></name>, <name><surname>van Gelder</surname><given-names>T</given-names></name>, <name><surname>Hesselink</surname><given-names>DA</given-names></name>, <name><surname>Haufroid</surname><given-names>V</given-names></name>, <name><surname>van Schaik</surname><given-names>RH</given-names></name>. <article-title>CYP3A4*22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy</article-title>. <source>Pharmacogenomics</source>. <year>2013</year>;<volume>14</volume>(<issue>1</issue>):<fpage>47</fpage>&#x02013;<lpage>62</lpage>. <pub-id pub-id-type="doi">10.2217/pgs.12.187</pub-id> .<pub-id pub-id-type="pmid">23252948</pub-id></mixed-citation></ref><ref id="pone.0165631.ref022"><label>22</label><mixed-citation publication-type="journal"><name><surname>Kuehl</surname><given-names>P</given-names></name>, <name><surname>Zhang</surname><given-names>J</given-names></name>, <name><surname>Lin</surname><given-names>Y</given-names></name>, <name><surname>Lamba</surname><given-names>J</given-names></name>, <name><surname>Assem</surname><given-names>M</given-names></name>, <name><surname>Schuetz</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title>Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression</article-title>. <source>Nature genetics</source>. <year>2001</year>;<volume>27</volume>(<issue>4</issue>):<fpage>383</fpage>&#x02013;<lpage>91</lpage>. <pub-id pub-id-type="doi">10.1038/86882</pub-id> .<pub-id pub-id-type="pmid">11279519</pub-id></mixed-citation></ref><ref id="pone.0165631.ref023"><label>23</label><mixed-citation publication-type="journal"><name><surname>Hustert</surname><given-names>E</given-names></name>, <name><surname>Haberl</surname><given-names>M</given-names></name>, <name><surname>Burk</surname><given-names>O</given-names></name>, <name><surname>Wolbold</surname><given-names>R</given-names></name>, <name><surname>He</surname><given-names>YQ</given-names></name>, <name><surname>Klein</surname><given-names>K</given-names></name>, <etal>et al</etal>
<article-title>The genetic determinants of the CYP3A5 polymorphism</article-title>. <source>Pharmacogenetics</source>. <year>2001</year>;<volume>11</volume>(<issue>9</issue>):<fpage>773</fpage>&#x02013;<lpage>9</lpage>. .<pub-id pub-id-type="pmid">11740341</pub-id></mixed-citation></ref><ref id="pone.0165631.ref024"><label>24</label><mixed-citation publication-type="journal"><name><surname>van Schaik</surname><given-names>RH</given-names></name>, <name><surname>van der Heiden</surname><given-names>IP</given-names></name>, <name><surname>van den Anker</surname><given-names>JN</given-names></name>, <name><surname>Lindemans</surname><given-names>J</given-names></name>. <article-title>CYP3A5 variant allele frequencies in Dutch Caucasians</article-title>. <source>Clin Chem</source>. <year>2002</year>;<volume>48</volume>(<issue>10</issue>):<fpage>1668</fpage>&#x02013;<lpage>71</lpage>. .<pub-id pub-id-type="pmid">12324482</pub-id></mixed-citation></ref><ref id="pone.0165631.ref025"><label>25</label><mixed-citation publication-type="other">European Centre for Disease Prevention and Control, WHO Regional Office for Europe. HIV/AIDS surveillance in Europe 2014. Stockholm: ECDC; 2015. Available: <ext-link ext-link-type="uri" xlink:href="http://ecdc.europa.eu/en/publications/Publications/hiv-aids-surveillance-in-Europe-2014.pdf">http://ecdc.europa.eu/en/publications/Publications/hiv-aids-surveillance-in-Europe-2014.pdf</ext-link>.</mixed-citation></ref><ref id="pone.0165631.ref026"><label>26</label><mixed-citation publication-type="other">Institut scientifique de Sant&#x000e9; publique (WIV-ISP). &#x000c9;pid&#x000e9;miologie du SIDA et de l'infection &#x000e0; VIH en Belgique. Situation au 31d&#x000e9;cembre 2014. Available: <ext-link ext-link-type="uri" xlink:href="https://epidemio.wiv-isp.be/ID/reports/Rapport_VIH-SIDA_2014.pdf">https://epidemio.wiv-isp.be/ID/reports/Rapport_VIH-SIDA_2014.pdf</ext-link>.</mixed-citation></ref><ref id="pone.0165631.ref027"><label>27</label><mixed-citation publication-type="other">Centers for Disease Control and Prevention (CDC): HIV Among African Americans. 2015. Available: <ext-link ext-link-type="uri" xlink:href="http://www.cdc.gov/hiv/group/racialethnic/africanamericans/">http://www.cdc.gov/hiv/group/racialethnic/africanamericans/</ext-link>.</mixed-citation></ref><ref id="pone.0165631.ref028"><label>28</label><mixed-citation publication-type="journal"><name><surname>Elens</surname><given-names>L</given-names></name>, <name><surname>Veriter</surname><given-names>S</given-names></name>, <name><surname>Yombi</surname><given-names>JC</given-names></name>, <name><surname>Di Fazio</surname><given-names>V</given-names></name>, <name><surname>Vanbinst</surname><given-names>R</given-names></name>, <name><surname>Lison</surname><given-names>D</given-names></name>, <etal>et al</etal>
<article-title>Validation and clinical application of a high performance liquid chromatography tandem mass spectrometry (LC-MS/MS) method for the quantitative determination of 10 anti-retrovirals in human peripheral blood mononuclear cells</article-title>. <source>J Chromatogr B Analyt Technol Biomed Life Sci</source>. <year>2009</year>;<volume>877</volume>(<issue>20&#x02013;21</issue>):<fpage>1805</fpage>&#x02013;<lpage>14</lpage>. Epub 2009/06/03. <pub-id pub-id-type="doi">10.1016/j.jchromb.2009.04.046</pub-id> .<pub-id pub-id-type="pmid">19487167</pub-id></mixed-citation></ref><ref id="pone.0165631.ref029"><label>29</label><mixed-citation publication-type="journal"><name><surname>Kakuda</surname><given-names>TN</given-names></name>, <name><surname>Abel</surname><given-names>S</given-names></name>, <name><surname>Davis</surname><given-names>J</given-names></name>, <name><surname>Hamlin</surname><given-names>J</given-names></name>, <name><surname>Scholler-Gyure</surname><given-names>M</given-names></name>, <name><surname>Mack</surname><given-names>R</given-names></name>, <etal>et al</etal>
<article-title>Pharmacokinetic interactions of maraviroc with darunavir-ritonavir, etravirine, and etravirine-darunavir-ritonavir in healthy volunteers: results of two drug interaction trials</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2011</year>;<volume>55</volume>(<issue>5</issue>):<fpage>2290</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.01046-10</pub-id>
<pub-id pub-id-type="pmid">21383098</pub-id></mixed-citation></ref><ref id="pone.0165631.ref030"><label>30</label><mixed-citation publication-type="other">Sch&#x000f6;ller-Gy&#x000fc;re M, Woodfall B, De Marez T, De Smedt G, Peeters M, Vandermeulen K, et al. Pharmacokinetics of TMC125 with atazanavir and atazanavir/ritonavir. 8th International Congress on Drug Therapy in HIV infection. 12&#x02013;16 November 2006, Glasgow, UK:Poster P278.</mixed-citation></ref><ref id="pone.0165631.ref031"><label>31</label><mixed-citation publication-type="journal"><name><surname>Belkhir</surname><given-names>L</given-names></name>, <name><surname>De Laveleye</surname><given-names>M</given-names></name>, <name><surname>Vandercam</surname><given-names>B</given-names></name>, <name><surname>Zech</surname><given-names>F</given-names></name>, <name><surname>Delongie</surname><given-names>KA</given-names></name>, <name><surname>Capron</surname><given-names>A</given-names></name>, <etal>et al</etal>
<article-title>Quantification of darunavir and etravirine in human peripheral blood mononuclear cells using high performance liquid chromatography tandem mass spectrometry (LC-MS/MS), clinical application in a cohort of 110 HIV-1 infected patients and evidence of a potential drug-drug interaction</article-title>. <source>Clinical biochemistry</source>. <year>2016</year>;<volume>49</volume>(<issue>7&#x02013;8</issue>):<fpage>580</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/j.clinbiochem.2015.12.011</pub-id> .<pub-id pub-id-type="pmid">26742721</pub-id></mixed-citation></ref><ref id="pone.0165631.ref032"><label>32</label><mixed-citation publication-type="journal"><name><surname>Scholler-Gyure</surname><given-names>M</given-names></name>, <name><surname>Kakuda</surname><given-names>TN</given-names></name>, <name><surname>Sekar</surname><given-names>V</given-names></name>, <name><surname>Woodfall</surname><given-names>B</given-names></name>, <name><surname>De Smedt</surname><given-names>G</given-names></name>, <name><surname>Lefebvre</surname><given-names>E</given-names></name>, <etal>et al</etal>
<article-title>Pharmacokinetics of darunavir/ritonavir and TMC125 alone and coadministered in HIV-negative volunteers</article-title>. <source>Antivir Ther</source>. <year>2007</year>;<volume>12</volume>(<issue>5</issue>):<fpage>789</fpage>&#x02013;<lpage>96</lpage>. .<pub-id pub-id-type="pmid">17713162</pub-id></mixed-citation></ref><ref id="pone.0165631.ref033"><label>33</label><mixed-citation publication-type="journal"><name><surname>Boffito</surname><given-names>M</given-names></name>, <name><surname>Winston</surname><given-names>A</given-names></name>, <name><surname>Jackson</surname><given-names>A</given-names></name>, <name><surname>Fletcher</surname><given-names>C</given-names></name>, <name><surname>Pozniak</surname><given-names>A</given-names></name>, <name><surname>Nelson</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance</article-title>. <source>Aids</source>. <year>2007</year>;<volume>21</volume>(<issue>11</issue>):<fpage>1449</fpage>&#x02013;<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1097/QAD.0b013e3282170ab1</pub-id> .<pub-id pub-id-type="pmid">17589191</pub-id></mixed-citation></ref><ref id="pone.0165631.ref034"><label>34</label><mixed-citation publication-type="journal"><name><surname>Barrail-Tran</surname><given-names>A</given-names></name>, <name><surname>Yazdanpanah</surname><given-names>Y</given-names></name>, <name><surname>Goldwirt</surname><given-names>L</given-names></name>, <name><surname>Chene</surname><given-names>G</given-names></name>, <name><surname>Colin</surname><given-names>C</given-names></name>, <name><surname>Piketty</surname><given-names>C</given-names></name>, <etal>et al</etal>
<article-title>Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients</article-title>. <source>Aids</source>. <year>2010</year>;<volume>24</volume>(<issue>16</issue>):<fpage>2581</fpage>&#x02013;<lpage>3</lpage>. .<pub-id pub-id-type="pmid">20960678</pub-id></mixed-citation></ref><ref id="pone.0165631.ref035"><label>35</label><mixed-citation publication-type="journal"><name><surname>Kakuda</surname><given-names>T</given-names></name>, <name><surname>Sekar</surname><given-names>V</given-names></name>, <name><surname>Vis</surname><given-names>P</given-names></name>, <name><surname>Coate</surname><given-names>B</given-names></name>, <name><surname>Ryan</surname><given-names>R</given-names></name>, <name><surname>Anderson</surname><given-names>D</given-names></name>, <etal>et al</etal>
<article-title>Pharmacokinetics and Pharmacodynamics of Darunavir and Etravirine in HIV-1-Infected, Treatment-Experienced Patients in the Gender, Race, and Clinical Experience (GRACE) Trial</article-title>. <source>AIDS research and treatment</source>. <year>2012</year>;<volume>2012</volume>:<fpage>186987</fpage>
<pub-id pub-id-type="doi">10.1155/2012/186987</pub-id>
<pub-id pub-id-type="pmid">22536495</pub-id></mixed-citation></ref><ref id="pone.0165631.ref036"><label>36</label><mixed-citation publication-type="journal"><name><surname>Hsu</surname><given-names>A</given-names></name>, <name><surname>Granneman</surname><given-names>GR</given-names></name>, <name><surname>Bertz</surname><given-names>RJ</given-names></name>. <article-title>Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents</article-title>. <source>Clin Pharmacokinet</source>. <year>1998</year>;<volume>35</volume>(<issue>4</issue>):<fpage>275</fpage>&#x02013;<lpage>91</lpage>. <pub-id pub-id-type="doi">10.2165/00003088-199835040-00002</pub-id> .<pub-id pub-id-type="pmid">9812178</pub-id></mixed-citation></ref><ref id="pone.0165631.ref037"><label>37</label><mixed-citation publication-type="journal"><name><surname>Josephson</surname><given-names>F</given-names></name>, <name><surname>Allqvist</surname><given-names>A</given-names></name>, <name><surname>Janabi</surname><given-names>M</given-names></name>, <name><surname>Sayi</surname><given-names>J</given-names></name>, <name><surname>Aklillu</surname><given-names>E</given-names></name>, <name><surname>Jande</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>CYP3A5 genotype has an impact on the metabolism of the HIV protease inhibitor saquinavir</article-title>. <source>Clinical pharmacology and therapeutics</source>. <year>2007</year>;<volume>81</volume>(<issue>5</issue>):<fpage>708</fpage>&#x02013;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1038/sj.clpt.6100117</pub-id> .<pub-id pub-id-type="pmid">17329995</pub-id></mixed-citation></ref><ref id="pone.0165631.ref038"><label>38</label><mixed-citation publication-type="journal"><name><surname>Zhang</surname><given-names>X</given-names></name>, <name><surname>Tierney</surname><given-names>C</given-names></name>, <name><surname>Albrecht</surname><given-names>M</given-names></name>, <name><surname>Demeter</surname><given-names>LM</given-names></name>, <name><surname>Morse</surname><given-names>G</given-names></name>, <name><surname>DiFrancesco</surname><given-names>R</given-names></name>, <etal>et al</etal>
<article-title>Discordant associations between SLCO1B1 521T&#x02014;&#x0003e;C and plasma levels of ritonavir-boosted protease inhibitors in AIDS clinical trials group study A5146</article-title>. <source>Ther Drug Monit</source>. <year>2013</year>;<volume>35</volume>(<issue>2</issue>):<fpage>209</fpage>&#x02013;<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1097/FTD.0b013e318280d0ad</pub-id>
<pub-id pub-id-type="pmid">23503447</pub-id></mixed-citation></ref><ref id="pone.0165631.ref039"><label>39</label><mixed-citation publication-type="other">Morlat P. Prise en charge m&#x000e9;dicale des personnes vivant avec le VIH. Recommandations du groupe d'experts&#x02014;Rapport 2013. 480 p.</mixed-citation></ref><ref id="pone.0165631.ref040"><label>40</label><mixed-citation publication-type="other">Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Accessed on 6/2/2016. Available: <ext-link ext-link-type="uri" xlink:href="http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf">http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf</ext-link>.</mixed-citation></ref></ref-list></back></article>